Pentamorphone for management of postoperative pain.

Abstract

The efficacy, duration, and safety of the synthetic opioid pentamorphone in the treatment of acute postoperative pain were evaluated in a randomized, double-blind study of 72 patients given 0.08, 0.16, or 0.24 micrograms/kg of pentamorphone or a placebo intravenously in the recovery room after major abdominal or orthopedic surgery. Only patients given 0.24 micrograms/kg of pentamorphone experienced decreased pain intensity and increased sedation, both transient in duration. Although the two higher doses of pentamorphone delayed the patient's request for supplemental morphine, the total amount of morphine required within the first hour was not different between treatments. No acute cardiorespiratory changes were observed. Pentamorphone (0.08-0.24 micrograms/kg) was ineffective for treating acute postoperative pain after major surgery.

• Authors: H Y Wong, R K Parker, R Fragen, P F White
• Journal: Anesthesia and analgesia (Anesth Analg) Vol. 72 Issue 5 Pg. 656-60 (May 1991) ISSN: 0003-2999 [Print] United States
• PMID: 1708214 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Analgesics
• pentamorphone
• Hydromorphone
• Fentanyl

Topics

• Adult
• Analgesics (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Fentanyl (pharmacology)
• Humans
• Hydromorphone (adverse effects, analogs & derivatives, therapeutic use)
• Injections, Intravenous
• Intraoperative Period
• Male
• Middle Aged
• Pain Measurement
• Pain, Postoperative (drug therapy)
• Randomized Controlled Trials as Topic